Artivion News

Oppenheimer Sticks to Its Buy Rating for Artivion (AORT)

TipRanksMay 7 08:17 ET

Artivion: Strong Q1 Performance and Raised Guidance Validate Buy Rating

TipRanksMay 7 07:38 ET

Artivion Analyst Ratings

BenzingaMay 7 05:54 ET

Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)

TipRanksMay 6 09:00 ET

Artivion Analyst Ratings

BenzingaApr 8 14:34 ET

Artivion's Growth Trajectory: A Buy Rating Amidst Promising Aortic Products and Financial Upswing

TipRanksApr 8 14:15 ET

Stifel Nicolaus Remains a Buy on Artivion (AORT)

TipRanksFeb 16 08:08 ET

Oppenheimer Sticks to Its Buy Rating for Artivion (AORT)

TipRanksFeb 16 07:56 ET

Artivion Secures Buy Rating: Strong Financials and Growth Trajectory Propel Price Target Increase

TipRanksFeb 16 05:56 ET

Artivion Analyst Ratings

BenzingaFeb 16 05:43 ET

Buy Rating on Artivion's Stock Backed by Strong PERSEVERE Study Results and Market Potential

TipRanksJan 30 10:16 ET

Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Artivion (AORT) and Apollo Medical Holdings (AMEH)

TipRanksJan 30 08:50 ET

Lake Street Keeps Their Buy Rating on Artivion (AORT)

TipRanksJan 22 14:24 ET

Artivion (AORT) Gets a Buy From Stifel Nicolaus

TipRanksJan 22 14:23 ET

Needham Reiterates Buy on Artivion, Maintains $22 Price Target

BenzingaDec 7, 2023 05:47 ET

Artivion Analyst Ratings

BenzingaDec 7, 2023 05:45 ET

Oppenheimer Sticks to Their Buy Rating for Artivion (AORT)

TipRanksNov 3, 2023 08:14 ET

Needham Maintains Buy on Artivion, Lowers Price Target to $22

BenzingaNov 3, 2023 06:53 ET

Artivion Analyst Ratings

BenzingaNov 3, 2023 06:51 ET

Promising Clinical Outcomes and Growth Potential Drive Buy Rating for Artivion

TipRanksOct 6, 2023 09:55 ET